HANCOCK JAFFE LABORATORIES overview

Live video webcast presentation on Wednesday, March 8 th at 9:10 AM ET IRVINE, CA / ACCESSWIRE / February 8, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, CEO of enVVeno Medical , will present at Cowen's 43 rd Annual Health Care Conference on Wednesday, March 8, 2023 at 9:10 AM ET. The conference incorporates presentations, fireside chats and...

Dr. Alavi is a highly accomplished medical device executive with proven track record of successfully leading R&D, Quality Assurance, Regulatory Affairs, and Manufacturing organizations across a number of companies within the cardiac and vascular space IRVINE, CA / ACCESSWIRE / January 18, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the promotion of Dr. Hamed Alavi to...

First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 3 years post-surgery No venous ulcer recurrences or CVI relapses Stability in improvements for all study endpoints including reflux, disease severity (rVCSS), and pain (VAS) IRVINE, CA / ACCESSWIRE / November 17, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Principal Investigator...

The Company submitted safety data for the first 20 patients enrolled in the ongoing SAVVE U.S. pivotal study for the VenoValve Following the initial safety data review by the FDA, the SAVVE study is cleared to continue without modification or interruption The Company currently has 33 patients enrolled in the study and expects to be fully enrolled by the end of Q2 of 2023 With $42.7 million of cash and investments reported at the end of Q3 of 2022, the Company has sufficient cash to sustain...

- Ended the quarter with $42.7 million in cash and investments - Burn rate of $4.5 million for the quarter - Runway extends through the end of 2024 including release of SAVVE topline pivotal trial data and initiation of TAVVE first in human study IRVINE, CA / ACCESSWIRE / October 27, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today provided a corporate update and reported financial...

- Ended the quarter with $51.3 million in cash - expected to fund operations through the end of 2024 including release of topline pivotal trial data - Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients - Progress on development of second device for the treatment of venous disease expected to be unveiled in mid-2022 IRVINE, CA / ACCESSWIRE / May 2, 2022 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards...

- Expanding patent portfolio bolsters protection of the Company's lead product -The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg - There are currently no effective treatments for patients with deep venous CVI - The VenoValve is currently being evaluated in leading hospitals throughout the U.S. in the ongoing SAVVE U.S pivotal trial IRVINE, CA / ACCESSWIRE / April 11, 2022 / enVVeno Medical...

Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data Nine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal Trial Continued Advancement in Development of Second Device for the Treatment of Venous Disease Expected To Be Unveiled in Mid-2022 IRVINE, CA / ACCESSWIRE / March 28, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the...